Journals / Klinik Psikiyatri Dergisi / 2020 / Cilt: 23 - Sayı: 1

Psychopharmacological treatment in COVID-19 pandemic

COVID-19 pandemisinde psikofarmakolojik tedavi

Pages
52–66
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also regardless of drug interactions, the antiviral effects of chlorpromazine and lithium and their place in the potential treatment of COVID-19 are mentioned and potential problems that psychiatric therapies may cause in these patients are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The COVID-19 infection is still active both worldwide and in our country.
📊
Key Findings & Data:So, it is very important to consider the interactions of psychotropic drugs used in the COVID-19 pandemic in patients receiving psychiatric treatment or planned to start psychiatric treatment.
💡
Conclusion & Impact:Also regardless of drug interactions, the antiviral effects of chlorpromazine and lithium and their place in the potential treatment of COVID-19 are mentioned and potential problems that psychiatric therapies may cause in these patients are discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The COVID-19 infection is still active both worldwide and in our country. Hereafter, it is going to have marked effects on clinical psychiatric practice. So, it is very important to consider the interactions of psychotropic drugs used in the COVID-19 pandemic in patients receiving psychiatric treatment or planned to start psychiatric treatment. There is still no cure for COVID-19 infection and treatment algorithms change over time. Moreover, studies on drug interactions between the drugs used in COVID-19 treatment and psychotropic drugs to guide the clinician are limited. In this regard, it is thought that it is important for psychiatrists to keep up with the current literature knowledge while planning psychotropic medication during the pandemic process, which is expected to continue for a long time. In this article, the mechanisms of action and interactions of frequently used drugs in the treatment of COVID-19 with psychotropic drugs such as hydroxychloroquine, favipiravir, oseltamivir, remdesivir, tocilizumab and azithromycin are reviewed. Also regardless of drug interactions, the antiviral effects of chlorpromazine and lithium and their place in the potential treatment of COVID-19 are mentioned and potential problems that psychiatric therapies may cause in these patients are discussed.

Özet

COVID-19 enfeksiyonu tüm dünyada ve ülkemizde halen etkisini sürdürmekte olup önümüzdeki süreçte psikiyatri pratiğinde dikkate alınması gerekecektir. Bu açıdan psikiyatrik tedavi almakta olan ya da psikiyatrik tedavi başlanması planlanan hastalarda COVID-19 pandemisinde kullanılan ilaçların psikotrop ilaçlarla etkileşimlerinin ele alınması oldukça önemlidir. COVID-19 enfeksiyonunun halen kesin bir tedavisi bulunmamakta ve tedavi algoritmaları zaman içerisinde değişiklik göstermektedir. Ayrıca COVID-19 tedavisinde kullanılan bazı ilaçların psikotroplarla etkileşimlerine dair klinisyene yol gösterecek çalışmalar kısıtlıdır. Bu açıdan uzun bir süre daha devam etmesi beklenen pandemi sürecinde psikiyatri hekimlerinin psikotrop ilaç tedavilerini planlarken bu konuda mevcut literatür bilgisine hakim olmalarının önemli olduğu düşünülmektedir. Buradan yola çıkılarak bu yazıda; hidroksiklorokin, favipiravir, oseltamivir, remdesivir, tosilizumab ve azitromisin gibi COVID-19 tedavisinde sık kullanılan ilaçların etki mekanizmaları ve psikotrop ilaçlarla etkileşimleri gözden geçirilmiştir. Ayrıca klorpromazin ve lityumun antiviral etkilerine ve COVID-19’un potansiyel tedavisindeki yerine değinilmiş; ilaç etkileşimlerinden bağımsız olarak bu hastalarda psikiyatrik tedavilerin yol açabileceği olası sorunlar da tartışılmıştır.

🔖

Cite This Article

TATLI, S. Z., ÇAKAR, G., ÇOLAK, B., KIZIL, E. T. Ö. (2020). Psychopharmacological treatment in COVID-19 pandemic. Klinik Psikiyatri Dergisi, Cilt: 23 - Sayı: 1, 52–66. https://ajindex.com/articles/211119

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua C. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Annals of the rheumatic diseases. 2018;77:98-103
  2. WHO. Clinical management of COVID-19: interim guidance, 27 May 2020. 2020
  3. Rainsford K, Parke AL, Clifford-Rashotte M, Kean W. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231-69
  4. Projean D, Baune B, Farinotti R, Flinois J-P, Beaune P, Taburet A-M, Ducharme J. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metabolism and Disposition. 2003;31(6):748-54
  5. Browning DJ. Pharmacology of chloroquine and hydroxychloroquine. Hydroxychloroquine and chloroquine retinopathy: Springer; 2014. p. 35-63
  6. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology. 2020:1-12
  7. Weniger H. Review of side effects and toxicity of chloroquine. Geneva: World health Organization; 1979
  8. Altintas E. Hydroxychloraquine-induced acute psychotic disorder in a female patient with rheumatoid arthritis: a case report. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. 2015;28(4):369
  9. Liverpool Uo. COVID-19 Drug Interactions 2020 [Available from:
  10. UpToDate. Lexicomp Drug Interactions [Available from: https://www.uptodate.com/drug-interactions/?source=responsive_home - di-druglist
  11. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings. British journal of pharmacology. 2012;165:289-312
  12. Mardones PS, Langenegger IQ, Thormann MA, Gesche CS, Selman AB. Hypoglycemia due to hydroxychloroquine an uncommon association but to keep in mind case report and review of literature. Journal of Diabetes, Metabolic Disorders & Control. 2020;7(7)
  13. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. International journal of clinical pharmacy. 2011;33:484
  14. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Bar